SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), an organization advancing a pivotal trial in Alzheimer’s illness with topline knowledge anticipated within the fourth quarter of 2021 and a rising pipeline of therapeutics for degenerative ailments, right now introduced that it’ll host a key opinion chief (KOL) webinar collection on its lead drug candidate atuzaginstat (COR388), a lysine-gingipain inhibitor. The webinar collection shall be held in two elements: Half 1 shall be on Friday, July 23, 2021, at 10:00 a.m. ET, and Half 2 shall be on Friday, July 30, 2021, at 10:00 a.m. ET. The collection is being performed at the side of Cortexyme’s participation on the Worldwide Affiliation for Dental Analysis (IADR) Common Session & Exhibition and Alzheimer’s Affiliation Worldwide Convention 2021 (AAIC) at which the corporate will current new baseline knowledge from its pivotal GAIN Trial, along with offering additional proof that P. gingivalis acts upstream of Alzheimer’s pathologies and atuzaginstat’s position in successfully blocking downstream illness.
Half 1: Innovation in Periodontal Illness – A Main Unmet Medical Want
The webinar will characteristic KOL Mark Ryder, D.M.D., (College of California, San Francisco) who will talk about the unmet medical want in treating sufferers with P. gingivalis-induced periodontal illness and current knowledge from two abstracts at IADR, entitled “Gingipain Inhibitors Penetrate and Inhibit Gingipains In Porphyromonas gingivalis Biofilms” (summary #3571509) and “Novel Lysine-Gingipain Inhibitor Atuzaginstat (COR388) Is Efficacious in a Mouse Mannequin of Periodontal Illness” (summary #1756).
Cortexyme’s administration staff will even present an replace on REPAIR, its ongoing Part 2 periodontal sub-study of atuzaginstat, as a part of its pivotal Part 2/3 GAIN Trial. Prime-line knowledge from the 233-subject REPAIR research is anticipated within the fourth quarter 2021. Dr. Ryder and Cortexyme’s administration shall be out there to reply questions following the formal displays.
To register for this webinar, please click on here.
Half 2: Innovation in Alzheimer’s Illness – Attending to the Root Explanation for Neurodegeneration
The webinar will characteristic KOL Marwan Noel Sabbagh, M.D., (Cleveland Clinic) who will talk about the present remedy panorama of Alzheimer’s illness and dementia, the unmet medical want, in addition to current exercise and proof to help the position of P. gingivalis as an essential upstream driver of Alzheimer’s illness pathology. Dr. Sabbagh will even handle new baseline knowledge from Cortexyme’s pivotal Part 2/3 GAIN Trial of atuzaginstat for the remedy of Alzheimer’s illness being introduced at AAIC 2021.
Cortexyme’s administration staff will present an replace on its ongoing pivotal Part 2/3 GAIN Trial, which builds on Part 1 knowledge demonstrating atuzaginstat was effectively tolerated in each wholesome topics and in sufferers with Alzheimer’s illness. The GAIN Trial is totally enrolled and top-line knowledge is anticipated within the fourth quarter 2021. Dr. Sabbagh and Cortexyme’s administration shall be out there to reply questions following the formal displays.
To register for this webinar, please click on here.
Mark Ryder, D.M.D., is a Professor of Periodontology and former Chair of Periodontology and Director of the Postgraduate program in Periodontology on the College of California, San Francisco the place he has been a college member for the previous 41 years. He obtained his dental and specialty coaching from the Harvard Faculty of Dental Drugs. He’s the creator of over 190 articles, abstracts, and guide chapters and has lectured extensively on a wide range of analysis and academic matters. He serves as an Affiliate Editor of the Journal of Periodontal Analysis and is on the Editorial Board of a number of dental analysis journals. He has additionally served as a chair and/or reviewer on a number of NIH research sections and different nationwide and worldwide peer evaluation grant organizations, along with serving as a marketing consultant for a number of nationwide and worldwide accreditation applications for dental training. His present analysis pursuits embrace connections between periodontal ailments and Alzheimer’s Illness, the hyperlinks between oral and systemic well being in HIV sufferers, and primary analysis and scientific trials on novel periodontal therapies.
Marwan Noel Sabbagh, M.D., board licensed neurologist and geriatric neurologist, hopes to work himself out of a job. Thought of one of many main specialists in Alzheimer’s and dementia, he’s the Camille and Larry Ruvo Endowed Chair for Mind Well being and Director of Translational Analysis at Cleveland Clinic Lou Ruvo Middle for Mind Well being in Las Vegas. Dr. Sabbagh has devoted his profession to discovering a remedy for Alzheimer’s and different age-related neurodegenerative ailments. Dr. Sabbagh is a number one investigator for a lot of outstanding nationwide Alzheimer’s prevention and remedy trials. Dr. Sabbagh is on the editorial board for Journal of Alzheimer’s Illness and BMC Neurology. He’s now editor in chief of Neurology and Remedy. He has authored and co-authored nearly 370 medical and scientific articles on Alzheimer’s analysis. Dr. Sabbagh is the creator of The Alzheimer’s Reply: Cut back Your Danger and Maintain Your Mind Wholesome, with foreword by Justice Sandra Day O’Connor, and The Alzheimer’s Prevention Cookbook: 100 Recipes to Increase Mind Well being. He has edited Palliative Take care of Superior Alzheimer’s and Dementia: Pointers and Requirements for Proof Based mostly Care and Geriatric Neurology revealed in 2014 and Preventing for my Life: residing within the shadow of Alzheimer’s illness revealed in 2019. He has been acknowledged with quite a few awards, together with WestMarc Innovator Award, 2015; Fellow of the American Academy of Neurology, 2004. Dr. Sabbagh earned his undergraduate diploma from the College of California, Berkeley and his medical diploma from the College of Arizona in Tucson. He obtained his residency coaching in neurology at Baylor Faculty of Drugs, Houston, Texas, and accomplished his fellowship in geriatric neurology and dementia on the College of California, San Diego Faculty of Drugs, the place he served on the college as assistant professor. Earlier than becoming a member of the college of the Cleveland Clinic, he was on the Barrow Neurological Institute the place he served for 3 years, and previous to that he was the director of the Banner Solar Well being Analysis Institute for 15 years.
Cortexyme, Inc. (Nasdaq: CRTX) is a scientific stage biopharmaceutical firm pioneering upstream therapeutic approaches designed to enhance the lives of sufferers identified with Alzheimer’s and different degenerative ailments. The corporate is advancing its disease-modifying pivotal GAIN Trial in gentle to average Alzheimer’s illness with top-line knowledge anticipated within the fourth quarter of 2021, along with rising a proprietary pipeline of first-in-class small molecule therapeutics for Parkinson’s illness, periodontitis, and different ailments with excessive unmet scientific want. Cortexyme’s lead program targets a particular, infectious pathogen referred to as P. gingivalis discovered within the mind and different organs and tied to degeneration and irritation in people and animal fashions. The corporate’s causation proof for Alzheimer’s illness and the mechanism of its novel therapeutic has been independently replicated and confirmed by a number of laboratories world wide, in addition to revealed in peer-reviewed scientific journals. To be taught extra about Cortexyme, go to www.cortexyme.com or observe @Cortexyme on Twitter.
Statements on this information launch comprise “forward-looking statements” which are topic to substantial dangers and uncertainties. Ahead-looking statements contained on this information launch could also be recognized by means of phrases akin to “anticipate,” “anticipate,” “consider,” “will,” “could,” “ought to,” “estimate,” “undertaking,” “outlook,” “forecast,” or different comparable phrases. Examples of forward-looking statements embrace, amongst others, statements we make relating to our enterprise plans, technique, timeline, prospects, and milestone expectations; the timing and success of the corporate’s scientific trials and associated knowledge, together with with respect to the GAIN and REPAIR Trials; the potential of atuzaginstat to deal with Alzheimer’s illness, periodontal illness, and different potential indications; and the timing of bulletins and updates referring to its scientific trials and associated knowledge. Ahead-looking statements are primarily based on Cortexyme’s present expectations and are topic to inherent uncertainties, dangers, and assumptions which are tough to foretell and will trigger precise outcomes to vary materially from what the corporate expects. Additional, sure forward-looking statements are primarily based on assumptions as to future occasions that won’t show to be correct. Components that might trigger precise outcomes to vary embrace, however are usually not restricted to, the dangers and uncertainties described within the part titled “Danger Components” in Cortexyme’s Annual Report on Kind 10-Ok filed with the Securities and Alternate Fee (SEC) on March 1, 2021, its Quarterly Report on Kind 10-Q filed with the SEC on Might 6, 2021, and different stories as filed with the SEC. Ahead-looking statements contained on this information launch are made as of this date, and Cortexyme undertakes no obligation to replace such info besides as required underneath relevant legislation.